Results for the six months ended February 28, 2019 are not necessarily an indication of the results that may be expected for the full fiscal year ending August 31, 2019.
The Company is party to certain lawsuits in the ordinary course of business.
The Company procures components from a broad group of suppliers.
Includes $0.3 million and $2.1 million recorded in the EMS segment and $0.5 million and $3.3 million recorded in the DMS segment for the three months ended February 28, 2019 and 2018, respectively.
The increase in cash flow from investing activities and the corresponding decrease to cash flow from operating activities upon adoption of the standard was $96.8 million and $1.2 billion for the six months ended February 28, 2019 and 2018, respectively.
The amounts for the three months and six months ended February 28, 2018, include a reduction to income tax expense related to derivative instruments of $3.5 million and $7.0 million, respectively.
Includes $4.7 million and $8.0 million recorded in the EMS segment, $2.1 million and $7.9 million recorded to the DMS segment and $0.0 million and $0.9 million of non-allocated charges for the six months ended February 28, 2019 and 2018, respectively.
The Company is one of the leading providers of worldwide manufacturing services and solutions.
 Item 1A.
Amounts are net of tax, which are immaterial for the three months and six months ended February 28, 2019.
Servicing fees related to each of the programs recognized during the three months and six months ended February 28, 2019 and 2018 were not material.
The Company provides comprehensive electronics design, production and product management services to companies in various industries and end markets.Net revenue increased during the three months ended February 28, 2019, compared to the three months ended February 28, 2018.
Research and development expenses remained consistent as a percentage of net revenue during the three months and six months ended February 28, 2019, compared to the three months and six months ended February 28, 2018.
Specifically, the DMS segment revenues increased 2% due to (i) a 4% increase in revenues from existing customers in our healthcare business and (ii) a 1% increase in revenues spread across various industries within the DMS segment.
Selling, general and administrative expenses increased during the three months ended February 28, 2019, compared to the three months ended February 28, 2018.
The decrease was partially offset by a 4% increase in revenues from existing customers in our healthcare business.
The strategic collaboration expands our medical device manufacturing portfolio, diversification and capabilities.